PMCB

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

PharmaCyte Biotech Inc

NASDAQ | PMCB

0.97

USD

$0.00

(

0.00%

)

At Close (As of Oct 16, 2025)

$6.86M

Market Cap

16.83

P/E Ratio

0.06

EPS

$2.42

52 Week High

$0.80

52 Week Low

HEALTHCARE

Sector

PMCB Chart

Recent Chart
Price Action

PMCB Technicals

Tags:

PMCB Earnings

Yearly Income Statement (As of Apr 30, 2025)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.4M
Selling General And Administrative $3.9M
Research And Development $438K
Operating Expenses $4.4M
Investment Income Net -
Net Interest Income $1.4M
Interest Income $1.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $31M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations $31M
Comprehensive Income Net Of Tax -
Ebit -$4.4T
Ebitda $31M
Net Income $31M

Revenue & Profitability

Earnings Performance

PMCB Financials

yearly Balance Sheet (As of Apr 30, 2025)

Field Value (USD)
Total Assets $55M
Total Current Assets $22M
Cash And Cash Equivalents At Carrying Value $15M
Cash And Short Term Investments $15M
Inventory -
Current Net Receivables $3.7M
Total Non Current Assets $33M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $1.5M
Intangible Assets Excluding Goodwill $1.5M
Goodwill -
Investments -
Long Term Investments $22M
Short Term Investments $366K
Other Current Assets $3.1M
Other Non Current Assets -
Total Liabilities $3.3M
Total Current Liabilities $2.9M
Current Accounts Payable $399K
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $363K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $2.5M
Other Non Current Liabilities -
Total Shareholder Equity $52M
Treasury Stock -
Retained Earnings -$85M
Common Stock $2.2K
Common Stock Shares Outstanding $7.3M

yearly Cash Flow (As of Apr 30, 2025)

Field Value (USD)
Operating Cashflow -$3M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $4
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$7M
Cashflow From Financing -$25M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout $1.1M
Dividend Payout Common Stock $1.1M
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$25M
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income $31M

yearly Income Statement (As of Apr 30, 2025)

Field Value (USD)
Gross Profit -
Total Revenue $0
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$4.4M
Selling General And Administrative $3.9M
Research And Development $438K
Operating Expenses $4.4M
Investment Income Net -
Net Interest Income $1.4M
Interest Income $1.4M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -
Income Before Tax $31M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations $31M
Comprehensive Income Net Of Tax -
Ebit -$4.4T
Ebitda $31M
Net Income $31M

PMCB News

PMCB Profile

PharmaCyte Biotech Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

PharmaCyte Biotech Inc. (PMCB) is a clinical-stage biotechnology company headquartered in Laguna Hills, California, focused on developing cutting-edge cell therapies for cancer and diabetes. Utilizing its proprietary technology platform, the company aims to create transformative treatments that enhance patient outcomes and overall quality of life. With a strategic emphasis on advancing its clinical programs, PharmaCyte Biotech is well-positioned to make significant contributions to the rapidly evolving biopharmaceutical sector, potentially addressing unmet medical needs and driving value for investors.

VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
-17.95%
$0.33
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
NAYA
+85.67%
$1.40
IVF
+85.67%
$1.40
CGBS
-39.47%
$0.03
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
SCNX
-17.63%
$0.58
F
-0.17%
$11.74
BBD
+1.71%
$3.25
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
FEMY
+35.37%
$0.74
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
AAL
-4.88%
$11.89
CLF
-2.79%
$13.56
MARA
-11.27%
$20.26
GDXD
-10.23%
$0.60
LAES
-15.08%
$6.36
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
RF
-5.61%
$23.35
GNPX
-43.39%
$0.47
QBTS
-9.64%
$40.46
BTG
+3.96%
$5.89
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-5.78%
$0.36
LGCB
+19.39%
$1.97
ABAT
-36.64%
$5.67
NAK
-4.34%
$2.64
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
RGTZ
+29.08%
$11.23
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
UUUU
-13.20%
$21.69
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
T
+0.49%
$26.20
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
JBLU
-3.63%
$4.76
CLSK
-13.92%
$19.97
APLD
-2.96%
$36.64
SMR
-10.87%
$47.62
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
BAC
-4.03%
$50.17
JOBY
-8.69%
$16.07
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
TOVX
-48.34%
$0.43
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-5.05%
$51.08
HIMS
-6.07%
$58.94
VHAI
-20.00%
$0.00
VIVK
-1.72%
$0.28
YYAI
-10.71%
$0.12
BURU
-17.95%
$0.33
RXRX
-6.33%
$6.36
EPWK
+26.46%
$0.09
BITF
-18.39%
$5.28
NAYA
+85.67%
$1.40
IVF
+85.67%
$1.40
CGBS
-39.47%
$0.03
NVDA
+1.10%
$181.81
PLUG
-8.70%
$3.51
YDKG
-49.73%
$0.09
ADAP
+6.02%
$0.19
BYND
-22.39%
$0.52
NVTS
+3.10%
$15.63
RGTI
-14.85%
$47.97
DNN
-2.83%
$3.08
NIO
-1.09%
$6.74
MIRA
+36.36%
$1.80
SCNX
-17.63%
$0.58
F
-0.17%
$11.74
BBD
+1.71%
$3.25
KVUE
-13.22%
$14.11
ACHR
-8.90%
$11.87
INTC
-0.83%
$36.84
TLRY
-8.33%
$1.54
HPE
-10.06%
$22.52
FEMY
+35.37%
$0.74
TSLA
-1.47%
$428.75
IONZ
+19.44%
$3.44
ONDS
-13.77%
$8.19
CAN
-14.79%
$1.67
AMD
-1.69%
$234.56
DFLI
-32.48%
$1.33
SOFI
+0.57%
$28.03
AXDX
-61.36%
$0.03
ETHD
+6.47%
$3.78
RIG
-2.56%
$3.22
AAL
-4.88%
$11.89
CLF
-2.79%
$13.56
MARA
-11.27%
$20.26
GDXD
-10.23%
$0.60
LAES
-15.08%
$6.36
AMC
-2.30%
$2.75
BTBT
-9.11%
$3.69
RF
-5.61%
$23.35
GNPX
-43.39%
$0.47
QBTS
-9.64%
$40.46
BTG
+3.96%
$5.89
QS
-13.41%
$15.45
VSEE
-13.85%
$0.51
RR
-7.95%
$5.67
GPUS
-5.78%
$0.36
LGCB
+19.39%
$1.97
ABAT
-36.64%
$5.67
NAK
-4.34%
$2.64
SNAP
-1.89%
$7.76
QUBT
-11.72%
$18.73
QSI
-3.42%
$2.54
CIFR
-10.98%
$18.72
RGTZ
+29.08%
$11.23
WOK
+1.55%
$0.05
CRML
-14.52%
$19.42
UUUU
-13.20%
$21.69
IREN
-9.04%
$61.83
ASST
-6.24%
$0.90
PFE
-0.65%
$24.23
MASK
+17.35%
$0.57
KEY
-5.35%
$16.78
HBAN
-5.00%
$15.39
T
+0.49%
$26.20
PLTR
-0.83%
$178.12
SOUN
-2.99%
$20.76
AMZN
-0.51%
$214.47
MU
+5.51%
$202.53
JBLU
-3.63%
$4.76
CLSK
-13.92%
$19.97
APLD
-2.96%
$36.64
SMR
-10.87%
$47.62
FNB
-7.21%
$14.65
WTO
-88.87%
$0.13
RMBL
+60.50%
$3.21
GRAB
-3.54%
$5.71
AAPL
-0.75%
$247.45
WULF
-10.40%
$13.86
NOK
+0.35%
$5.67
ADD
-25.47%
$0.05
SOND
+79.34%
$1.65
AUUD
+0.97%
$2.06
BAC
-4.03%
$50.17
JOBY
-8.69%
$16.07
SLNH
-2.33%
$4.19
IONQ
-9.41%
$65.59
TOVX
-48.34%
$0.43
NEHC
+9.12%
$3.35
SRM
+53.27%
$10.30
SATL
-29.71%
$2.91
BMNR
-5.05%
$51.08
HIMS
-6.07%
$58.94
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.